Anti-PCSK9 antibodies with pH-dependent binding characteristics
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsGeorge D. Yancopoulos, Nicholas J. Papadopoulos, Andrew J. Murphy, Neil Stahl
Life of this patent
Estimating the term…
Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsGeorge D. Yancopoulos, Nicholas J. Papadopoulos, Andrew J. Murphy, Neil Stahl
Estimating the term…
The present invention provides antibodies and antigen-binding fragments thereof that specifically bind proprotein convertase subtilisin/kexin-9 (PCSK9) with greater affinity at neutral pH than at acidic pH. The antibodies of the invention may possess one or more amino acid changes as compared to antibodies that do not exhibit pH-dependent binding properties. For example, the present invention includes anti-PCSK9 antibodies which possess one or more histidine substitutions in one or more complementarity determining regions. The antibodies of the invention, with pH-dependent binding properties, remain in circulation and exhibit cholesterol lowering activity for prolonged periods of time in animal subjects as compared to anti-PCSK9 antibodies that do not exhibit pH-dependent binding properties. The antibodies of the invention are therefore useful for treating diseases and disorders related to elevated HDL cholesterol, wherein the antibodies of the invention can be administered to a patient at a lower dose and/or with less frequent dosing as compared to antibodies that do not exhibit pH-dependent binding properties.
An isolated antibody or antigen-binding fragment thereof that binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the acidic/neutral KD ratio for the antibody or antigen-binding fragment binding to PCSK9 at 25° C. is greater than about 12.5 as determined by surface plasmon resonance;
Dependencies are inferred from the claim text.